Cancer clinical trials in the region Île-de-France
750 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 2
Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN)
#NCT04419649
#2023-507469-24-00
Partie 1 Escalade de dose
Required histologic types
Myelodysplastic syndromes (MDS)
Required histologic sub types
MDS de novo
Required number of previous lines of therapy
None
1
Required previous treatments
Systemic Treatment-Naive
EPO / Growth factors
Required medullary blasts
< 5 %
Required IPSS-R prognostic scores
Very low
Low
Intermediate
Excluded genetic anomalies
del(5q)
Excluded previous treatments
Chemotherapy
Erythroid maturation agent
Immunomodulator
5 recruiting sites
Takeda
Phase 2
Bladder / Urinary Tract / Urethral cancer
#NCT07265947
#2025-523539-20-00
Required histologic types
Upper excretory tract cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Localized
Excluded previous treatments at localized stage
Targeted therapy
Radiotherapy
2 recruiting sites
Tyra Biosciences, Inc
Phase 2
Lung cancer
#NCT06712316
#2024-515764-31-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
EGFR
Excluded previous treatments at localized stage
Immunotherapy
Chemotherapy
Targeted therapy
Bispecific T-cell engager antibodies
Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Targeted therapy
Bispecific T-cell engager antibodies
24 recruiting sites
BioNTech SE
Phase 2
Lung cancer
#NCT04919811
#2024-516604-41-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
ROS-1
10 recruiting sites
Thérapeutique AnHeart Inc
Phase 2
Acute leukemia
#NCT07570173
#2025-522267-15-00
Required histologic types
Acute lymphoblastic leukemia (ALL)
Required histologic sub types
B-cell (B-ALL)
Required immunophenotypic profiles
CD19
Required number of previous lines of therapy
1
2
3 or more
Excluded genetic anomalies
Ph+ (Philadelphia chromosome positive)
Excluded previous treatments
Systemic Treatment-Naive
1 recruiting site
Merck Sharp & Dohme LLC
Phase 2
Breast cancer
#NCT06486883
#2024-512360-55-00
Required HER2 statuses
HER2 Ultra Low
HER2 Low
Required HR statuses
HR Positive
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
MedSIR
Phase 2
Prostate cancer
#NCT07287150
#2025-521327-67-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at localized stage
Hormone therapy
Required previous treatments at advanced or metastatic stage
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Chemotherapy
4 recruiting sites
Hoffmann-La Roche
Phase 2
Colon cancer
Rectal cancer
Anal cancer
Pancreas cancer
Liver and bile duct cancer
Stomach and esophageal cancer
Small intestine and appendix cancer
#NCT07539311
#2025-524130-26-00
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
Genmab
Phase 2
Head and neck cancer
#NCT07529873
#2025-521437-88-00
Required histologic types
Oral cavity
Oropharynx
Hypopharynx
Larynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
1
Required previous treatments at localized stage
Radiochemotherapy
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Radiochemotherapy
Excluded previous treatments at localized stage
Immunotherapy
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Targeted therapy
1 recruiting site
Groupe Oncologie Radiothérapie Tête et Cou (GORTEC)
Phase 2
Prostate cancer
#NCT06582628
#2023-510536-37-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
None
1
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Hormone therapy
5 recruiting sites
Fundacion Oncosur